Sinan Wang, PhD, joined the ShanghaiTech University in 2021 as a tenure-track Assistant Professor in the School of Biomedical Engineering. Dr. Wang obtained his PhD degree in East China University of Science and Technology. Dr. Wang completed his postdoc training in University of California, San Francisco and subsequently became an associate professional researcher.

Dr. Wang has worked in PET probe development and radionuclide therapy for many years. His research aims to explore the potential of novel biomarkers as a nuclear medicine target, and develop new drugs as molecular imaging probes. His lab needs different specialties in medicinal chemistry, biological evaluation and molecular imaging. Dr. Wang has published over 20 papers, including several first-author papers such as Clin. Cancer. Res and J. Am. Chem. Soc.  

• Development and optimization of PET probe targeting novel biomarkers

• Radionuclide therapy for cancer treatment

• Development of efficient radiolabeling methodology

• Development of boron neutron capture therapy (BNCT) reagents

Reviewer for journals:

• Molecular Pharmaceutics

• The Journal of Organic Chemistry

Member for associations or committees:

• Society of Nuclear Medicine and Molecular Imaging (SNMMI)

• American Chemical Society

• Yirong Zhang^†, Chuwei Yu^†, Linyuan Wang, Lina Zhou, Chaofan Li, Changxian Yuan, Nan Sun, Guanxiang Hao, Chenyang Ma, Yuzhe Lin, Hongjing Li, Jiali Hong, Jinhua Zhao, Kaiyan Lou, Rui Zhang,* Chengying Xie,* and Sinan Wang*. Synthesis and Anticancer Activity Evaluation of Novel Carborane-Containing Isoflavonoid Analogues. ACS Omega. 2025, 10, 18720-18732.

• Chaofan, Li, Xinyi He, Changrui Wei, Changxian Yuan, Xiaoqin Shen, Zhiguang Zhang*, Bin Cui*, Sinan Wang*. Organocatalytic Enantioselective Nucleophilic Substitution of Furfurals with Alcohols via a Remote Chiral Control. J. Org. Chem. 2025, 90, 3301−3307.

• Chaofan Li^†, Yingshuang Zhang^†, Ziyin Zhang, Yirong Zhang, Yuxuan Song, Linyuan Wang, Changxian Yuan, Guanxiang Hao, Nan Sun, Hongjing Li, Zhiguang Zhang, Yundong He*, Sinan Wang*. Discovery and biological evaluation of carborane-containing derivatives as TEAD auto palmitoylation inhibitors. Bioorg. Med. Chem. Lett. 2025, 121, 130155.

• Anju Wadhwa^†, Sinan Wang^†, Bonell Patiño-Escobar, Anil P Bidkar, Kondapa Naidu Bobba, Emily Chan, Niranjan Meher, Scott Bidlingmaier, Yang Su, Suchi Dhrona, Huimin Geng, Vishesh Sarin, Henry F VanBrocklin, David M Wilson, Jiang He, Li Zhang, Veronica Steri, Sandy W Wong, Thomas G Martin, Youngho Seo, Bin Liu, Arun P Wiita, Robert R Flavell. CD46-targeted Theranostics for Positron Emission Tomography and ²²⁵Ac-Radiopharmaceutical Therapy of Multiple Myeloma.Clin. Cancer Res.2024, 30, 1009-1021.

• Anil P. Bidkar^†, Sinan Wang^†, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, and Robert R. Flavell. Treatment of Prostate Cancer with CD46-targeted ²²⁵Ac Alpha Particle Radioimmunotherapy. Clin. Cancer Res.2023, 29, 1916-1928.

• Jonathan Chou^†, Emily A. Egusa^†, Sinan Wang^†, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, Veronica Steri, Jiaoti Huang, Yuzhuo Wang, Eric J. Small, Emily Chan, Bradley A. Stohr, Alan Ashworth, Brant Delafontaine, Sylvie Rottey, Keegan S. Cooke, Nooshin Hashemi Sadraei, Brian Yu, Mark Salvati, Julie M. Bailis, Felix Y. Feng, Robert R. Flavell, and Rahul Aggarwal. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Research2023, 83, 301-315.

• Sinan Wang^†, Jun Li^†, Jun Hua^† Yang Su, Denis Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony Huynh, Ning Zhao, Yung-Hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Jonathan Chou, Felix Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell*, Jiang He*. Molecular imaging of prostate cancer targeting CD46 using immunoPET. Clin. Cancer Res.2021, 5, 1305-1315.

• Sinan Wang, Charles Blaha, Raquel Santos, Tony Huynh, Thomas R. Hayes, Denis R. Beckford-Vera, Joseph E. Blecha, Andrew S. Hong, Miko Fogarty, Thomas A. Hope, David R. Raleigh, David M. Wilson, Michael J. Evans, Henry F. VanBrocklin, Tomoko Ozawa, Robert R. Flavell. Synthesis and initial biological evaluation of boron-containing prostate specific membrane antigen ligands for treatment of prostate cancer using boron neutron capture therapy. Mol. Pharmaceutics. 2019, 16, 3831-3841.

• Sinan Wang, David E. Korenchan, Paola Perez Rivera, Céline Taglang, Thomas Hayes, Renuka Sriram, Robert Bok, Andrew Hong, Henry Li, David M. Wilson, John Kurhanewicz, Robert R. Flavell.Amino Acid-Derived Sensors For Specific Zn²⁺ Detection Using Hyperpolarized ¹³C Magnetic Resonance Spectroscopy.Chem. - A Eur. J.2019, 25, 11842-11846.

• Sinan Wang, Xiangmin Li, Hongwei Liu, Li Xu, Jinchen Zhuang, Jian Li, Hao Li, and Wei Wang.Organocatalytic enantioselective direct addition of aldehydes to 4-vinylpyridines and electrondeficient vinylarenes and their synthetic applications.J. Am. Chem. Soc., 2015, 137, 2303-2310.

The Molecular Imaging and Radionuclide Therapy Lab aims to develop novel PET imaging probes and radionuclide therapeutic reagents for early-stage tumor diagnosis, drug evaluation and better understanding of disease mechanism. Training opportunities in our lab are by nature interdisciplinary to meet the special challenge for nuclear medicine which requires specialties in medicinal chemistry, radiochemistry and biomedical engineering. Our lab focuses on the following research fields: 

• Development of novel PET probes

• Radionuclide therapy for cancer treatment

• Application of PET imaging in drug development